Background {#Sec1}
==========

Schizophrenia is a debilitating psychiatric disorder resulting from abnormal brain development. Previous studies suggest that the etiology of schizophrenia is a combination of genetics and environmental factors, which lead to mal-development of the central nervous system (CNS) and impaired neurotransmission \[[@CR1], [@CR2]\]. Neurodevelopmental aberrations influenced by neurotrophic factors (NFs) are important paradigms in understanding schizophrenia pathogenesis.

Brain-derived neurotrophic factor (BDNF), as one of NFs, is thought to be the key in the development and maintenance of cortical neurons and synapses. BDNF is widely distributed in the CNS and plays an important role in the survival, differentiation and growth of neurons during the developmental stages in neonatal individuals, synaptic plasticity and behavior in adulthood \[[@CR3], [@CR4]\]. Many evidences suggest that BDNF is involved in the pathophysiological process of schizophrenia \[[@CR5]\]. Previous studies have shown that peripheral BDNF in patients with chronic or first-episode schizophrenia are decreased, while BDNF mRNA was reduced in the postmortem brain of patients \[[@CR6]--[@CR8]\]. However, other reports have shown inconsistent results \[[@CR9]\]. BDNF is also associated with learning and memory, as demonstrated in gene knockout animal model \[[@CR10]\]. Schizophrenics have a wide range of cognitive deficits, such as learning, memory, executive function and attention. Animal models and clinical trials have also shown that BDNF levels are positively correlated with cognitive impairment \[[@CR8], [@CR11]--[@CR13]\]. Glial cell **line-**derived neurotrophic factor (GDNF) is one of the most potent trophic factors for dopaminergic neurons of the mammalian CNS. The most prominent feature of GDNF is its ability to support the survival of dopaminergic and motorneurons. GDNF heterozygous mutant mice showed the impaired water-maze learning performance, indicating its role in cognitive abilities \[[@CR14]\]. Therefore, GDNF may be potentially relevant to the dopaminergic and neurodevelopmental hypothesis of schizophrenia. Four studies published so far on GDNF serum levels in schizophrenia \[[@CR8], [@CR15]--[@CR17]\] have shown inconsistent results, two of which suggested that serum GDNF levels were associated with cognitive function \[[@CR8], [@CR15]\]. Considering these conflicting results, the relationship between NFs and schizophrenia needs to be studied further. The inconsistency of previous studies on the association of BDNF and GDNF with schizophrenia may be related to the confounding effects of the severity of symptoms, age, gender, sample population, different stages of illness and medication history. However, since schizophrenia is a complex and heterogeneous disorder, studying specific clinical phenotypes rather than the whole spectrum would be more beneficial to better understand the disease.

Since Carpenter described deficit schizophrenia (DS) in a homogeneous subclass of schizophrenia patients characterized by primary and continuous negative symptoms, a large number of studies have shown that the deficit and non-deficit forms of schizophrenia (DS and NDS) differ in several parameters, such as biological correlates, risk factors, etiological factors and treatment response \[[@CR18]\]. There is mounting evidences that DS may be a distinct subtype of schizophrenia, which may help to reduce the heterogeneity of this disease. Akyol et al. reported that the serum BDNF levels in DS were significantly lower than those in the healthy individuals, while those in NDS patients were similar to normal levels \[[@CR19]\]. In contrast, Valiente-Gómez et al. did not find any significant differences across the three groups \[[@CR20]\]. To our best knowledge, there is no report on serum levels of GDNF in DS patients, neither literatures on the association between serum BDNF or GDNF concentrations and cognitive dysfunction in DS patients.

Although there have been inconsistencies in the studies that investigated the BDNF and GDNF levels in patients with schizophrenia; the majority of the studies revealed that these two NFs are closely related to the pathological process of this disease \[[@CR7]--[@CR9], [@CR15]--[@CR17]\]. At present, the research on BDNF levels in DS patients is also inconsistent. Therefore, the present study aimed to probe whether there is a discrepancy between patients with DS, NDS, and healthy controls (HC) in terms of serum BDNF and GDNF levels. Meanwhile, we would like to evaluate the relationship between BDNF or GDNF levels and cognitive impairment in DS.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

A total of 109 consecutive male patients with clinically stable schizophrenia from the Wutaishan Hospital of Yangzhou, Jiangsu Province, and 40 sex and age matched HC were recruited for this study. All patients met the Diagnostic Interview and the Diagnostic and Statistical Manual-IV (DSM-IV) criteria for schizophrenia, which was confirmed by two independent senior psychiatrists on the basis of the Structured Clinical Interview for DSM-IV (SCID). In addition, the patients had the chronic course of disease at least 5 years, and had received stable doses of oral antipsychotic drugs for at least 12 months before recruitment. As the patients were prescribed different antipsychotic drugs, all drugs were converted into chlorpromazine equivalents in order to compare the medium dose of antipsychotics between DS and NDS groups. DS diagnosis was confirmed based on the Chinese version of the Schedule for Deficit Syndrome (SDS-C) \[[@CR21]\]. The enrolled patients were divided into 51 DS and 58 NDS based on the SDS-C. Exclusion criteria included a history of head injury, neurological disorders, dementia, mental retardation or significantly impaired vision and red-green colorblindness, comorbidities involving major organs, alcohol/substance abuse or dependence, and electroconvulsive therapy.

Healthy controls with no personal or family history of psychiatric disorders were recruited through advertisements in the local community. None of them had any history of drug and alcohol abuse/dependence, nor significantly impaired vision and red-green colorblindness. All subjects were Han Chinese aged between 30 and 60 years, and were assessed in terms of weight and height in order to calculate their body mass index (BMI). The study protocol was approved by the ethical review committee of the local hospital, and all subjects participated after giving written informed consent.

Assessment of clinical symptoms {#Sec4}
-------------------------------

Two psychiatrists with minimum 5 years' experience in clinical practice assessed the psychopathology of the patients using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), and the Scale for the Assessment of Positive Symptoms (SAPS). To ensure consistency and reliability of ratings across the participants, the two psychiatrists attended a training session on these clinical scales prior to the study. The 18-item BPRS was classified into positive, negative, disorganized, and affect symptom subscores based on the findings of the most comprehensive factor analysis \[[@CR22]\].

Neurocognitive assessments {#Sec5}
--------------------------

Processing speed, attention, executive function, and working memory were assessed by classical neuropsychological tests like Digit Vigilance test (DVT), Verbal Fluency tests (VFT-animals and VFT-actions), Stroop Color-Word test (SCWT), Block Design (Wechsler adult intelligence scale-Chinese Revision WAIS-RC), and Paced Auditory Serial Addition Test (PASAT). The cognitive functions of all subjects were examined by two experienced psychiatrics in a fixed test laboratory.

Measurement of serum BDNF and GDNF levels {#Sec6}
-----------------------------------------

Serum samples from all participants were collected between 7 and 9 a.m. at the same time following an overnight fast, and stored at − 80 °C till analysis. Serum BDNF and GDNF levels were measured by ELISA according to the manufacturer's instructions (Promega, Madison, WI, USA). Each sample was tested twice for BDNF and GDNF levels and the mean of two measurements were used for statistical analysis. Inter- and intra-assay variation coefficients of each NF were less than 5%.

Statistical analysis {#Sec7}
--------------------

All data were analyzed using the Statistical Package for Social Sciences (SPSS) version 13.0. Test scores are presented as means with standard deviations. Categorical variables were analyzed by the chi-square test. Probability values were based on two-samples t-tests or one-way analysis of variance (ANOVA) for continuous variables. Bonferroni test was used as the post hoc test of ANOVA. There were significant differences of education duration among three groups, therefore education duration was performed as a covariate in the comparison of neuropsychological performances and NFs levels by the analysis of covariance (ANCOVA) with post hoc Bonferroni correction as appropriate. When comparing the cognitive performance and NFs levels between the DS and NDS group, the BPRS negative symptoms and SANS scores were performed as a covariate because they were higher in the DS group than in the NDS group. Correlation analysis was performed by partial correlation test. For all analyses, the significance level (*p* value) was set at 0.05.

Results {#Sec8}
=======

Sample characteristics {#Sec9}
----------------------

As shown in Table [1](#Tab1){ref-type="table"}, no significant differences were present between the patients and HC in terms of age and BMI, except for education (*p =* 0.023). There were also no significant differences in the age of onset, duration of illness, and smoking ratio between the two patient groups. In addition, their antipsychotic medication doses were similar when converted to equivalent doses of chlorpromazine \[[@CR23]\]. As expected, the DS patients showed more severe total and negative psychopathological symptoms (all *p* \< 0.001) than the NDS patients, but both groups had similar positive, affect or disorganized symptoms (all *p* \> 0.05). None of the patients were receiving antidepressant or mood-stabilizing drugs. Table 1Demographic and clinical characteristics of DS and NDS patients and healthy controlsDeficit schizophrenia (DS; *N* = 51)Nondeficit schizophrenia (NDS; *N* = 58)Healthy controls (HC; *N* = 40)*F/t/χ2p* ValueAge (years)50.24 ± 6.8547.90 ± 6.8446.78 ± 10.732.2450.110Education (years)8.71 ± 2.448.79 ± 2.1910.08 ± 3.213.8570.023BMI (kg/m^2^)25.10 ± 1.2825.21 ± 1.1724.82 ± 1.161.2120.301Age of Onset (years)22.02 ± 2.7522.16 ± 2.91--−0.2490.804Duration of illness(years)28.22 ± 6.1325.74 ± 6.94--1.9620.052Chlorpromazine eguivalents (mg)462.65 ± 238.61524.48 ± 211.00--−1.4360.154Smoking ratio (%)54.9069.00--2.2870.130BPRS score Positive symptoms6.35 ± 1.166.45 ± 1.20--−0.4200.675 Negative symptoms12.43 ± 1.787.47 ± 1.25--17.028\< 0.001 Disorganized symptoms6.75 ± 1.576.59 ± 1.04--0.6280.531 Affect syndromes6.67 ± 1.117.02 ± 1.32--−1.4920.139 Sum32.18 ± 3.1727.52 ± 2.86--8.070\< 0.001SAPS total score9.76 ± 3.8410.31 ± 4.69--−0.6590.511SANS total score57.41 ± 9.3032.62 ± 7.51--15.385\< 0.001*BMI* body mass index, *BPRS* brief psychiatric rating scale, *SAPS* the Scale for the Assessment of Positive Symptoms, *SANS* the Scale for the Assessment of Negative Symptoms

Cognitive performance in schizophrenia and HC {#Sec10}
---------------------------------------------

The performance of cognitive tests is summarized in Table [2](#Tab2){ref-type="table"}. The inter-group differences were analyzed by ANOVA, which indicated significant differences in the overall scores (all *p* \< 0.001). Post hoc analysis revealed that the DS group performed significantly worse than the HC as well as the NDS group in terms of overall cognitive test scores. The NDS group also performed significantly worse than the HC group in all cognitive tests (all *p* \< 0.01), except for DVT (*p* \> 0.05). Table 2Comparison of neuropsychological performances among DS and NDS patients and healthy controlsDeficit schizophrenia (DS,*N* = 51)Nondeficit schizophrenia (NDS,*N* = 58)Healthy controls (HC,*N* = 40)F*p* ValueDVT (seconds)347.14 ± 238.41^\*\*^203.10 ± 93.88^\#\#^133.31 ± 45.6622.553\< 0.001Stroop words only40.67 ± 20.13^\*\*^58.16 ± 18.22^\#\#^79.03 ± 17.13^△△^42.790\< 0.001Stroop colors only25.37 ± 12.49^\*\*^36.00 ± 12.03^\#\#^50.68 ± 17.21^△△^34.160\< 0.001Stroop interference16.67 ± 9.79^\*\*^22.59 ± 8.67^\#\#^30.60 ± 10.91^△△^19.982\< 0.001WAIS-RS(Block Design)13.67 ± 8.70^\*\*^20.90 ± 6.84^\#\#^33.18 ± 7.02^△△^68.015\< 0.001PASAT correct15.55 ± 8.05^\*\*^26.26 ± 8.51^\#\#^34.68 ± 10.63^△△^47.827\< 0.001PASAT try17.82 ± 9.04^\*\*^30.24 ± 8.77^\#\#^38.28 ± 9.93^△△^54.236\< 0.001Category fluency score14.45 ± 5.14^\*\*^19.14 ± 7.69^\#\#^29.80 ± 9.15^△△^44.002\< 0.001^\*\*^*p* \< 0.001 DS vs. HC; ^\#\#^*p* \< 0.001 DS vs. NDS; ^△△^*p* \< 0.001 NDS vs. HC

Serum BDNF and GDNF in schizophrenia and HC {#Sec11}
-------------------------------------------

Serum BDNF levels were significantly lower in the patients compared to the HC (2.72 ± 1.85 ng/ml vs. 3.43 ± 1.71 ng/ml vs. 9.86 ± 4.01 ng/ml, *F* = 96.456, *p* \< 0.001)(Fig. [1](#Fig1){ref-type="fig"}a). Furthermore, BDNF levels showed a tendency of decrease in the DS group than the NDS group, but without statistical significance (*p \>* 0.05). There was no significant difference in the GDNF levels of the patients (DS and NDS) and HC (527.32 ± 136.86 pg/ml vs. 587.03 ± 193.90 pg/ml vs. 547.49 ± 134.66 pg/ml, *F* = 1.992, *p* = 0.140) (Fig. [1](#Fig1){ref-type="fig"}b). Fig.1**a** Serum BDNF levels in DS and NDS patients and HC. **b** Serum GDNF levels in DS and NDS patients and HC. **a** shows that serum BDNF levels were significantly lower in the patients (DS:2.72 ± 1.85 ng/ml, NDS: 3.43 ± 1.71 ng/ml) compared to the HC (9.86 ± 4.01 ng/ml) (*F* = 96.456, *p* \< 0.001). But there is no difference in the BDNF levels between DS and NDS (*p* \> 0.05). **b** shows that there is no difference in the GDNF levels of the patients (DS and NDS) and HC (527.32 ± 136.86 pg/ml vs. 587.03 ± 193.90 pg/ml vs. 547.49 ± 134.66 pg/ml, *F* = 1.992, *p* = 0.140)

The relationships between BDNF or GDNF levels and cognitive functioning {#Sec12}
-----------------------------------------------------------------------

GDNF levels were positively correlated with scores of Stroop words only (*r* = 0.311, *p* = 0.033), Stroop colors only (*r* = 0.356, *p* = 0.014) and Stroop interference (*r* = 0.348, *p* = 0.016) in DS group (Fig. [2](#Fig2){ref-type="fig"}a, b and c). There were no correlations between either BDNF or GDNF levels and the cognitive tests in NDS and HC groups. Fig.2**a** Correlation between serum GDNF levels and the Stroop words in DS. **b** Correlation between serum GDNF levels and the Stroop colors in DS. **c** Correlation between serum GDNF levels and the Stroop interference in DS. **a**, **b** and **c** shows that GDNF levels were positively correlated with scores of Stroop words only (*r* = 0.311, *p* = 0.033), Stroop colors only (*r* = 0.356, *p* = 0.014) and Stroop interference (*r* = 0.348, *p* = 0.016) in DS group

Discussion {#Sec13}
==========

Our study for the first time detected serum BDNF and GDNF levels in patients with DS and NDS in Chinese population \[[@CR24]\]. Given that serum BDNF levels might be influenced by the menstrual cycle, we only chose male individuals as research subjects \[[@CR25]\]. It has been reported that the peripheral levels of BDNF can reflect the changes of CNS levels \[[@CR26]\]. A large amount of evidence showed BDNF may be related to the pathophysiology of schizophrenia because of its role in the development, regeneration, survival and maintenance of brain neurons \[[@CR9], [@CR27]\]. Some literatures reported that the levels of BDNF and TrkB receptor mRNA in prefrontal cortex and hippocampus of patients with chronic schizophrenia were significantly decreased \[[@CR28], [@CR29]\]. Our study also found a significant reduction of serum BDNF in the chronic schizophrenic patients (DS and NDS) compared to HC, which is consistent with many previous studies \[[@CR12], [@CR30]\]. However, no significant differences in serum BDNF were seen between the DS and NDS subgroups, while only a slight decrease was found in the DS patients. This is also consistent with a previous study showing decreased serum BNDF in the schizophrenic patients compared to the healthy individuals, without any significant difference between the DS and NDS subgroups \[[@CR20]\]. In another study, Akyol et al. reported reduced serum BDNF levels in the DS patients compared to the controls but no significant difference between the NDS and control groups \[[@CR19]\]. These contradictory findings may be attributed to confounding factors like the patients' age, gender, severity of the illness, treatment modules, and the genetic background of the patients. Notably, both male and female schizophrenic patients were included in Akyol's study.

To the best of our knowledge, this is the first study to explore the serum GDNF levels in DS patients. However, we didn't find any significant differences among the DS, NDS and HC groups in terms of serum GDNF, which is consistent with one recent study that reported similar serum GDNF levels in the chronic schizophrenia patients and controls \[[@CR15]\]. Another study also showed no differences in serum GDNF between female schizophrenia patients and healthy individuals \[[@CR16]\]. Our previous study have demonstrated that serum GDNF were significantly lower in drug-free schizophrenic patients than in healthy controls, and the reduced serum GDNF gradually returned to normal levels with the improvement in psychiatric symptoms following antipsychotic therapy \[[@CR31]\]. Increase in GDNF levels during treatment is in line with a few previous studies that showed that antipsychotic medications stimulated C6 glioma cells to secrete GDNF \[[@CR32]\], and enhanced GDNF signaling in experimental \[[@CR33]\] and clinical settings \[[@CR34]\]. In our study, the chronic schizophrenia patients had received long-term antipsychotic treatment during hospitalization, which likely altered their serum GDNF levels to near normal levels. Therefore, more detailed longitudinal studies are required to determine if GDNF may be associated with the pathogenesis of schizophrenia and the response to pharmacological treatment. In contrast, Tunca et al. reported lower serum GDNF levels in schizophrenic inpatients or outpatients who received antipsychotic and antidepressant treatment \[[@CR17]\]. The likely reasons for this discrepancy could be the different ages and antipsychotic drug doses in the two studies.

Another major finding of our study is the significant difference in the cognitive scores, except that for DVT, seen in the pairwise comparisons between DS, NDS and HC groups. These findings are consistent with that of our previous study indicating greater impairments in every neuropsychological measure and cognitive domain in the DS compared to the NDS patients \[[@CR35]\]. The present study provided evidence to support the hypothesis that the deficit syndrome may be a specific subgroup within schizophrenia. In addition, this is the first study to correlate BDNF and GDNF levels with cognitive dysfunction in DS and NDS patients. Consistent with one study reporting no correlation between the serum levels of BDNF and cognitive functions in schizophrenia patients \[[@CR36]\], we also found that BDNF serum levels were not related to cognitive function in DS, NDS, and HC groups. However, the reported BDNF levels in healthy controls were negatively correlated with verbal working memory in this article. In a recent study of a Chinese sample, the authors found that there was no correlation between serum BDNF levels and cognitive function in patients with first-episode schizophrenia and healthy controls \[[@CR37]\]. Our result contradicts previous studies on chronic schizophrenia patients \[[@CR12], [@CR13]\] and a recent meta-analysis \[[@CR5]\], which suggested that higher BDNF expression was associated with better neurocognitive performance in schizophrenia patients. Several factors can account for this discrepancy, such as different cognitive tests used, the duration of the illness, comorbidities, smoking, diet, obesity and even genetic background of the patients.

The third major finding of our study is that higher serum levels of GDNF are associated with better performance on Stroop words only, Stroop colors only and Stroop interference in the DS group. However, no significant correlations were observed between GDNF and cognitive test scores in either the NDS or HC groups. Stroop interference test is used to evaluate cognitive flexibility which is one of the critical roles of executive function domain, whereas Stroop words only and Stroop colors only test provides information on sustained attention. Our results indicate that lower GDNF serum levels in DS patients are related to more severe cognitive impairments in executive function and attention. GDNF is widely expressed in the brain and play particularly important roles in the physiology of catecholaminergic neurons \[[@CR38]\]. Moreover, it has been reported to be related to the development and maintenance of various types of neurons: dopaminergic, serotonergic, noradrenergic and GABAergic \[[@CR39]\], which are all involved in the pathological process of schizophrenia. Previous animal studies demonstrated that GDNF was closely related to learning and memory \[[@CR14], [@CR40]\] and GDNF+/− mutant mice exhibit abnormal hippocampal synaptic transmission \[[@CR41]\], indicative of a role for GDNF in cognitive abilities. These results may explain, to some extent, the association between serum GDNF with several subsets of cognitive abilities in DS patients in our study. However, one study has shown that higher GDNF levels result in more severe attention deficit in schizophrenia outpatients \[[@CR15]\]. But we found that lower serum levels of GDNF were associated with more severe cognitive impairment in attention distribution and verbal fluency in first-episode schizophrenics in our previous study \[[@CR8]\]. The differences of sample sources, subject characteristics, and study paradigms in these studies may be one of the reasons for the inconsistent findings.

Limitations of the study {#Sec14}
------------------------

Our study has several limitations. First, BDNF contains multiple proteolytic isoforms (pro-BDNF, truncated BDNF, mature BDNF) in the serum, but we only tested serum total BDNF levels. Carlino et al. confirmed that mature BDNF and pro-BDNF levels were increased while that of truncated BDNF was decreased in the schizophrenic patients, and low serum levels of the truncated BDNF isoform were associated with cognitive impairments \[[@CR42]\]. Therefore, the proteolytic isoforms of BDNF may affect the results of the present study. Second, we did not analyze the influence of inflammation on the correlation between BDNF and schizophrenia. Some studies reported that interactions between inflammatory factors and BDNF may be implicated in the pathophysiology and cognitive impairment seen in chronic schizophrenia \[[@CR43], [@CR44]\]. Therefore, an as yet unknown interaction between inflammatory factors and BDNF in DS may be an avenue worth researching further. Third, it is unclear whether GDNF content in serum is correlated with the brain GDNF content. Previous studies have found that GDNF had a very low capacity of crossing the blood-brain barrier \[[@CR45]\]. Fourth, this study is an exploratory analysis of a relatively small sample, but did not include correcting the correlations between NFs and cognitive performance for multiple comparisons. We attempt to increase the homogeneity of subjects by eliminating or minimizing confounding factors, such as gender, fluctuations of psychiatric symptoms and social environment, which will make it difficult to recruit DS and NDS patients. The present study included larger DS samples, compared with other published studies of NFs in this group. However, the limited power to be the current sample size means that we cannot accurately determine the different contributions of cognitive impairment and subgroup effects on NFs alterations. A larger sample size is needed to increase the statistical power in future research. Finally, all patients in our study had been receiving medications, and their effect on NFs could not be ruled out. In addition, as we only recruited male subjects, the future researches include both male and female participants would be needed.

Conclusions {#Sec15}
===========

In conclusion, our preliminary data suggests that serum BDNF level maybe not a suitable biomarker for DS, despite its significantly lower levels in the schizophrenia patients. In addition, the differences in the neurocognitive functions of DS and NDS patients support the concept of DS being a different clinical entity of schizophrenia. Although serum GDNF levels in the DS group were not significantly different from the NDS and HC groups, only the DS patients showed an association between higher serum GDNF levels with better cognitive performance, which indicates that GDNF may be a protective factor in maintaining cognitive function in DS. Therefore, future longitudinal studies that include untreated patients with DS would provide new insights.
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